GLB1: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Infobox | |||
| name = | {{Infobox gene | ||
| image = | | name = GLB1 | ||
| | | image = <!-- Image removed --> | ||
| | | caption = <!-- Caption removed --> | ||
| symbol = | | HGNCid = 4296 | ||
| | | symbol = GLB1 | ||
| OMIM = | | alt_symbols = ELNR1, EBP, MPS4B | ||
| | | EntrezGene = 2720 | ||
| | | OMIM = 611458 | ||
| | | RefSeq = NM_000404 | ||
| | | UniProt = P16278 | ||
| chromosome = 3 | |||
| arm = p | |||
| band = 21.33 | |||
}} | }} | ||
''' | '''GLB1''' is a [[gene]] that encodes the enzyme beta-galactosidase, which is involved in the [[metabolism]] of [[glycosaminoglycans]] and [[glycolipids]]. This enzyme is crucial for the [[lysosomal]] degradation of these substances. Mutations in the GLB1 gene can lead to several [[genetic disorders]]. | ||
== Function == | |||
The GLB1 gene provides instructions for making the enzyme beta-galactosidase. This enzyme is located in [[lysosomes]], which are compartments within cells that digest and recycle different types of molecules. Beta-galactosidase helps break down certain complex molecules, including [[glycosaminoglycans]] (GAGs) and [[glycolipids]]. | |||
== Clinical Significance == | |||
Mutations in the GLB1 gene are associated with several disorders: | |||
* [[GM1 gangliosidosis]]: A rare [[lysosomal storage disorder]] characterized by the accumulation of GM1 gangliosides in the [[central nervous system]] and other tissues. | |||
* [[Mucopolysaccharidosis type IVB]] (MPS IVB): Also known as Morquio B syndrome, this condition affects the [[skeletal system]] and other parts of the body. | |||
== Pathophysiology == | |||
In GM1 gangliosidosis, mutations in the GLB1 gene reduce or eliminate the activity of beta-galactosidase. As a result, GM1 gangliosides accumulate to toxic levels, particularly in the brain, leading to the neurological symptoms of the disorder. | |||
In MPS IVB, the deficiency of beta-galactosidase leads to the accumulation of [[keratan sulfate]], a type of glycosaminoglycan, causing skeletal abnormalities and other symptoms. | |||
== | == Diagnosis == | ||
Diagnosis of disorders related to GLB1 mutations typically involves: | |||
* [[Genetic testing]] to identify mutations in the GLB1 gene. | |||
* [[Enzyme assay]] to measure the activity of beta-galactosidase in [[blood]] or [[tissue samples]]. | |||
* | |||
* | |||
== | == Treatment == | ||
Currently, there is no cure for disorders caused by GLB1 mutations. Treatment focuses on managing symptoms and may include: | |||
* [[Supportive care]] | |||
* [[Physical therapy]] | |||
* [[Surgical interventions]] for skeletal abnormalities | |||
== | == See Also == | ||
* [[Lysosomal storage disease]] | |||
* [[Enzyme replacement therapy]] | |||
== | == References == | ||
{{Reflist}} | |||
== External Links == | |||
* [https://www.ncbi.nlm.nih.gov/gene/2720 GLB1 gene - NCBI] | |||
* [https://ghr.nlm.nih.gov/gene/GLB1 GLB1 - Genetics Home Reference] | |||
[[Category: | [[Category:Genes on human chromosome 3]] | ||
[[Category: | [[Category:Lysosomal storage disorders]] | ||
[[Category: | [[Category:Genetic disorders with OMIM but no gene]] | ||
Latest revision as of 20:44, 30 December 2024
| Symbol | GLB1 |
|---|---|
| HGNC ID | 4296 |
| Alternative symbols | – |
| Entrez Gene | 2720 |
| OMIM | 611458 |
| RefSeq | NM_000404 |
| UniProt | P16278 |
| Chromosome | 3p21.33 |
| Locus supplementary data | – |
GLB1 is a gene that encodes the enzyme beta-galactosidase, which is involved in the metabolism of glycosaminoglycans and glycolipids. This enzyme is crucial for the lysosomal degradation of these substances. Mutations in the GLB1 gene can lead to several genetic disorders.
Function[edit]
The GLB1 gene provides instructions for making the enzyme beta-galactosidase. This enzyme is located in lysosomes, which are compartments within cells that digest and recycle different types of molecules. Beta-galactosidase helps break down certain complex molecules, including glycosaminoglycans (GAGs) and glycolipids.
Clinical Significance[edit]
Mutations in the GLB1 gene are associated with several disorders:
- GM1 gangliosidosis: A rare lysosomal storage disorder characterized by the accumulation of GM1 gangliosides in the central nervous system and other tissues.
- Mucopolysaccharidosis type IVB (MPS IVB): Also known as Morquio B syndrome, this condition affects the skeletal system and other parts of the body.
Pathophysiology[edit]
In GM1 gangliosidosis, mutations in the GLB1 gene reduce or eliminate the activity of beta-galactosidase. As a result, GM1 gangliosides accumulate to toxic levels, particularly in the brain, leading to the neurological symptoms of the disorder.
In MPS IVB, the deficiency of beta-galactosidase leads to the accumulation of keratan sulfate, a type of glycosaminoglycan, causing skeletal abnormalities and other symptoms.
Diagnosis[edit]
Diagnosis of disorders related to GLB1 mutations typically involves:
- Genetic testing to identify mutations in the GLB1 gene.
- Enzyme assay to measure the activity of beta-galactosidase in blood or tissue samples.
Treatment[edit]
Currently, there is no cure for disorders caused by GLB1 mutations. Treatment focuses on managing symptoms and may include:
- Supportive care
- Physical therapy
- Surgical interventions for skeletal abnormalities
See Also[edit]
References[edit]
<references group="" responsive="1"></references>
